Literature DB >> 632366

Bioavailability of erythromycin ethylsuccinate in pediatric patients.

T C Coyne, S Shum, A H Chun, L Jeansonne, H C Shirkey.   

Abstract

A parallel treatment group bioavailability study was undertaken in children 6 to 65 months of age, comparing fasting and nonfasting erythromycin serum levels after a single oral dose of erythromycin ethylsuccinate granules. Results demonstrated significantly higher levels in the nonfasting than in the fasting state, while fasting state levels were comparable to those found in studies of adult subjects receiving recommended doses of the same compound.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 632366     DOI: 10.1002/j.1552-4604.1978.tb01593.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 3.  Interactions affecting drug absorption.

Authors:  P G Welling
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 4.  Acute otitis media: diagnosis and drug therapy.

Authors:  R H Schwartz; D M Schwartz
Journal:  Drugs       Date:  1980-02       Impact factor: 9.546

5.  [Tissue penetration of erythromycin (author's transl)].

Authors:  G A Dette
Journal:  Infection       Date:  1979       Impact factor: 3.553

6.  Influence of food on absorption of erythromycin ethyl succinate.

Authors:  P J Thompson; K R Burgess; G E Marlin
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  Effect of food on the absorption of hydralazine in man.

Authors:  R J Walden; R Hernandez; D Witts; B R Graham; B N Prichard
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.